HeartQuest Ventricular Assist Device Magnetically Levitated Centrifugal Blood Pump

Bearnson, Gill B.; Jacobs, G; Kirk, John; Khanwilkar, Pratap S.; Nelson, Karl E.; Long, James W.

doi:10.1111/j.1525-1594.2006.00223.x

Cited by 30 publications

(23 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These systems have demonstrated excellent blood compatibility, low hemolytic performance, and long durability, and some devices have now advanced into clinical applications for bridge-torecovery, bridge-to-transplantation, and destination therapy (4,(8)(9)(10)(11).…”

mentioning

confidence: 99%

Development of a Disposable Maglev Centrifugal Blood Pump Intended for One‐Month Support in Bridge‐to‐Bridge Applications: In Vitro and Initial In Vivo Evaluation

Someya¹,

Kobayashi

Waguri

et al. 2009

Artificial Organs

View full text Add to dashboard Cite

MedTech Dispo, a disposable maglev centrifugal blood pump with two degrees of freedom magnetic suspension and radial magnetic coupling rotation, has been developed for 1-month extracorporeal circulatory support. As the first stage of a two-stage in vivo evaluation, 2-week evaluation of a prototype MedTech Dispo was conducted. In in vitro study, the pump could produce 5 L/min against 800 mm Hg and the normalized index of hemolysis was 0.0054 +/- 0.0008 g/100 L. In in vivo study, the pump, with its blood-contacting surface coated with biocompatible 2-methacryloyloxyethyl phosphorylcholine polymer, was implanted in seven calves in left heart bypass. Pump performance was stable with a mean flow of 4.49 +/- 0.38 L/min at a mean speed of 2072.1 +/- 64.5 rpm. The maglev control revealed its stability in rotor position during normal activity by the calves. During 2 weeks of operation in two calves which survived the intended study period, no thrombus formation was seen inside the pump and levels of plasma free hemoglobin were maintained below 4 mg/dL. Although further experiments are required, the pump demonstrated the potential for sufficient and reliable performance and biocompatibility in meeting the requirements for cardiopulmonary bypass and 1-week circulatory support.

show abstract

mentioning

confidence: 99%

Development of a Disposable Maglev Centrifugal Blood Pump Intended for One‐Month Support in Bridge‐to‐Bridge Applications: In Vitro and Initial In Vivo Evaluation

Someya¹,

Kobayashi

Waguri

et al. 2009

Artificial Organs

View full text Add to dashboard Cite

show abstract

“…For the same reason, the team was also predisposed to the use of magnetic bearings, as opposed to hydrodynamic or contact bearings. According to members of the team who have had favorable experience with magnetically levitated pumps, the reduction of shear stress, Coulomb heat generation, and avoidance of seals or purge system outweighed the cost of added complexity 2,11,12,21,40,44…”

Section: Methodsmentioning

confidence: 99%

“…A methodology, developed in prior Levacor™ VAD11 and Streamliner™ VAD2 programs, entails the use of multiple reduced-order algebraic models for the fluid path(s), motor, suspension, rotordynamics, and heat transfer. These equations were implemented using Microsoft Excel® and MathCAD (PTC, Needham, MA, USA).…”

Section: Methodsmentioning

confidence: 99%

PediaFlow™ Maglev Ventricular Assist Device: A Prescriptive Design Approach

Antaki

Ricci

Verkaik

et al. 2010

Cardiovasc Eng Tech

View full text Add to dashboard Cite

This report describes a multi-disciplinary program to develop a pediatric blood pump, motivated by the critical need to treat infants and young children with congenital and acquired heart diseases. The unique challenges of this patient population require a device with exceptional biocompatibility, miniaturized for implantation up to 6 months. This program implemented a collaborative, prescriptive design process, whereby mathematical models of the governing physics were coupled with numerical optimization to achieve a favorable compromise among several competing design objectives. Computational simulations of fluid dynamics, electromagnetics, and rotordynamics were performed in two stages: first using reduced-order formulations to permit rapid optimization of the key design parameters; followed by rigorous CFD and FEA simulations for calibration, validation, and detailed optimization. Over 20 design configurations were initially considered, leading to three pump topologies, judged on the basis of a multi-component analysis including criteria for anatomic fit, performance, biocompatibility, reliability, and manufacturability. This led to fabrication of a mixedflow magnetically levitated pump, the PF3, having a displaced volume of 16.6 cc, approximating the size of a AA battery and producing a flow capacity of 0.3-1.5 L/min. Initial in vivo evaluation demonstrated excellent hemocompatibility after 72 days of implantation in an ovine. In summary, combination of prescriptive and heuristic design principles have proven effective in developing a miniature magnetically levitated blood pump with excellent performance and biocompatibility, suitable for integration into chronic circulatory support system for infants and young children; aiming for a clinical trial within 3 years.

show abstract

“…[42][43][44][45][46] These magnetically suspended, noncontacting pumps minimize stagnation and stasis, and have been associated with minimal to no embolic events following prolonged perfusion without anticoagulation. [42][43][44][45][46] Human trials with nonpulsatile VADs with advanced fluid dynamic designs have recently been published, 27,28,47 with some attenuation of thrombotic complications noted. However, significant anticoagulation has still been required for patient safety.…”

Section: Advances In Pump Design To Minimize Recirculation and Stasismentioning

confidence: 99%

Mechanical Circulatory Device Thrombosis: A New Paradigm Linking Hypercoagulation and Hypofibrinolysis

Nielsen¹,

Kirklin²,

Holman³

et al. 2008

ASAIO Journal

View full text Add to dashboard Cite

This review considers the perhaps unappreciated role of contact pathway proteins in the pathogenesis of thrombotic/thromboembolic morbidity associated with mechanical circulatory support. Placement of ventricular assist devices (VADs) has been associated with consumption of circulating contact proteins and persistent generation of activated contact proteins such as Factor XII and high molecular weight kininogen. Importantly, activated contact proteins are absorbed to the surface of VADs via the Vroman effect. Further, hyperfibrinogenemia and persistent platelet activation exist in patients with VADs, likely contributing to speed of clot growth. Using thrombelastographic-based analyses, it has been determined that contact pathway protein activated coagulation results in a thrombus that develops strength at a significantly faster rate that tissue factor initiated coagulation. Further, thrombelastographic analyses that include the addition of tissue-type plasminogen activator have demonstrated that contact protein pathway activation results in thrombin activatable fibrinolysis inhibitor activation to a far greater extent than that observed with tissue factor initiated coagulation, resulting in a thrombus that takes significantly longer to lyse. These observations serve as the rational basis for clinical investigation to determine if regional suppression of thrombin generation with FXII/high molecular weight kininogen inhibition in concert with thrombin-activatable fibrinolysis inhibitor inhibition may decrease mechanical circulatory support-associated thrombotic morbidity.

show abstract

HeartQuest Ventricular Assist Device Magnetically Levitated Centrifugal Blood Pump

Cited by 30 publications

References 4 publications

Development of a Disposable Maglev Centrifugal Blood Pump Intended for One‐Month Support in Bridge‐to‐Bridge Applications: In Vitro and Initial In Vivo Evaluation

Development of a Disposable Maglev Centrifugal Blood Pump Intended for One‐Month Support in Bridge‐to‐Bridge Applications: In Vitro and Initial In Vivo Evaluation

PediaFlow™ Maglev Ventricular Assist Device: A Prescriptive Design Approach

Mechanical Circulatory Device Thrombosis: A New Paradigm Linking Hypercoagulation and Hypofibrinolysis

Contact Info

Product

Resources

About